Journal of Clinical Medicine Research

Objective: To investigate the application efficacy of target-controlled infusion (TCI) anesthesia in minimally invasive neurosurgical procedures. Methods: Eighty-six patients undergoing minimally invasive neurosurgery from March 2024 to July 2025 were randomly assigned to a control group and an experimental group (n = 43 each). The control group received conventional continuous intravenous anesthesia, whereas the experimental group received TCI anesthesia with propofol and remifentanil. Both groups maintained BIS values between 45 and 55. Anesthesia-related time parameters, drug consumption, and the incidence of adverse events were compared. Results: The experimental group exhibited significantly shorter durations for anesthesia induction, postoperative emergence, and extubation compared to the control group (t = 8.724, 9.351, 10.126; all P < 0.05). Intraoperative consumption of propofol and remifentanil was significantly lower in the experimental group (t = 7.892, 8.563; all P < 0.05). The incidence of adverse events (4.65%) was significantly lower than that in the control group (18.60%) (χ² = 4.441, P < 0.05). Conclusion: TCI anesthesia enables precise control of anesthetic depth in minimally invasive neurosurgery, shortens recovery time, reduces drug dosage, maintains hemodynamic stability, and lowers the incidence of adverse events, demonstrating significant clinical value.